Last reviewed · How we verify
NCT07239544
Generation of Reactive T Cells Based on Tumor Whole Cell Antigen Nanovaccines
trial testing observational study in Lung Cancer (NSCLC) in 50 participants. Participants enrolled and being followed up; not accepting new ones.
10 July 2026
Quick facts
| Lead sponsor | The First Affiliated Hospital of Soochow University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 10 July 2025 |
| Primary completion | 10 July 2026 |
| Estimated completion | 10 July 2026 |
| Sites | 1 location across China |
Drugs / interventions tested
- observational study — full drug profile →
Conditions studied
- Lung Cancer (NSCLC) — all drugs for Lung Cancer (NSCLC) →
Sponsor
The First Affiliated Hospital of Soochow University
Who can join
Adults 18 to 90, any sex, with Lung Cancer (NSCLC). Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Tumor-reactive T cells are generated based on the tumor full antigen nanovaccine and the tumor-reactive T cells are reinjected for autologous therapy to provide the optimal treatment plan for clinical patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Organoids in Cancer Research and Regenerative Medicine: Current Status, Challenges, and Future Prospects.
Li R, Wu Y, Zheng Z, Zhou F, et al · · 2026 · cited 1× · PMID 41503026 · DOI 10.1002/mco2.70575
Verify or expand the search:
- PubMed search for NCT07239544
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of observational study
Trials testing the same drug.
- NCT07497139 — Sepsis Induced Myocardial Injury in Critically Ill Children · not yet recruiting
- NCT07379567 — BREVOC Study: Exhaled VOCs for High-Risk Chest Pain in the ED · not yet recruiting
- NCT07391007 — Integrated Clinical-molecular Risk Stratification to Early Recurrence in Colorectal Liver Metastases · not yet recruiting
- NCT07372183 — Wound Healing Following Extraction and Ridge Preservation in Smokers and Non-smokers · not yet recruiting
- NCT07310186 — Treatment and Outcomes of DLBCL After Progression on Polatuzumab Vedotin-based Combination Therapy · not yet recruiting
Other recruiting trials for Lung Cancer (NSCLC)
Currently open trials in the same condition.
- NCT07219251 — Engagement of Veterans With Lung Cancer · NA · recruiting
- NCT07379476 — Local Ablative Therapy to Oligoresidual Metastasis in EGFR Mutated Non-small Cell Lung Cancer · Phase 2 · recruiting
- NCT07103395 — A Study Evaluating Neoadjuvant Chemotherapy, Concurrent Chemoradiotherapy Combined With Dual Immune Checkpoint Blockade · Phase 2 · recruiting
- NCT06717295 — The CCANED-CIPHER Study: Early Cancer Detection and Treatment Response Monitoring Using AI-Based Platelet and Immune Cel · recruiting
- NCT07120282 — Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I NSCLC · Phase 2 · recruiting
Other The First Affiliated Hospital of Soochow University trials
Trials by the same sponsor.
- NCT07350863 — U69-CART-Cells For R/R T-ALL · Phase 1 · recruiting
- NCT06985498 — Immunotherapy Combined With Auto-HSCT and CD22/CD19 CAR-T Sandwich Strategy for B-ALL · Phase 2 · not yet recruiting
- NCT07463651 — MRD-guided Maintenance Post-HCT: Gilteritini vs Sorafenib · Phase 3 · recruiting
- NCT07500753 — A Single-arm, Prospective Study of a Clad-LABU Conditioning Regimen in HSCT for R/R MDS/AML in Elderly Patients · NA · recruiting
- NCT07511426 — U96-CAR-T-Cells For R/R B-ALL · Phase 1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT07239544 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by The First Affiliated Hospital of Soochow University
- Last refreshed: 20 November 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07239544.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing